

**Novel Oncology Therapeutics: Targeting Hope**  
**Live Virtual Course**  
**August 25, 2023**

*Premier Sponsor*



DAY 1 Friday, August 25, 2023		
Time (Mountain Time)	Topic	Presenter(s)
8:00-8:15 am	<b>Welcome and Introductions</b>	<i>Dr. Jenna Burton, Dr. Joelle Fenger</i>
8:15-9:45 am	<b>Lecture Series – The Expanding Clinical Role of Cancer Immunotherapy</b> <ul style="list-style-type: none"> <li>• Understand the therapeutic application, clinical indication, common treatment schedules, and toxicity profiles of adoptive T cell therapy</li> <li>• Recognize the clinical application and immunologic response assessment of checkpoint blockade therapy, as well as understand mechanisms of resistance and management of toxicities associated with checkpoint blockade</li> <li>• Describe the clinical application CAR T-cell therapy for solid tumors and understand the potential benefits and challenges of use in veterinary oncology.</li> <li>• Recognize clinical utility of repurposed medications to modulate tumor and tumor microenvironment interactions</li> <li>• Incorporate information discussed in this session into your clinical practice and client discussions</li> </ul>	<i>Dr. Brooke Fowler, Dr. Nicola Mason, Dr. Dan Regan</i>
9:45-10:00 am	<b>Break</b>	
10:00-11:00 am	<b>Interactive Discussion – Cancer Immunotherapy</b> <ul style="list-style-type: none"> <li>• Understand the therapeutic application, clinical indication, common treatment schedules, and toxicity profiles of adoptive T cell therapy.</li> <li>• Recognize the clinical application and immunologic response assessment of checkpoint blockade therapy, as well as understand mechanisms of resistance and management of toxicities associated with checkpoint blockade</li> <li>• Describe the clinical application CAR T-cell therapy for solid tumors and understand the potential benefits and challenges of use in veterinary oncology.</li> <li>• Recognize clinical utility of repurposed medications to modulate tumor and tumor microenvironment interactions</li> <li>• Incorporate information discussed in this session into your clinical practice and client discussions</li> </ul>	<i>Dr. Brooke Fowler, Dr. Nicola Mason, Dr. Dan Regan</i>  <i>Moderator: Dr. Joelle Fenger</i>

**Novel Oncology Therapeutics: Targeting Hope**  
**Live Virtual Course**  
**August 25, 2023**

*Premier Sponsor*



DAY 1 (continued) Friday, August 25, 2023		
Time (Mountain Time)	Topic	Presenter(s)
11:00am-12:00 pm	<p><b>Lecture Series – Targeted Therapies: Pre-Clinical and Pharmacologic Considerations</b></p> <ul style="list-style-type: none"> <li>Describe the methodology and model systems utilized to assess efficacy, tolerability, and dosing schedules for targeted therapeutics</li> <li>Recognize gaps in our knowledge regarding optimal dose and schedule for targeted therapeutics in veterinary cancer patients</li> <li>Understand limitations of extrapolating preclinical safety and tolerability data of targeted therapies to veterinary patients with cancer</li> <li>Understand the difference between FDA-approved and 503A and 503B compounded products</li> <li>Incorporate information discussed in this session into your clinical practice and client discussions</li> </ul>	<p><i>Dr. Luke Wittenberg, Dr. Heather Gardner, Dr. Lauren Forsythe</i></p>
12:00-12:15 pm	<b>Break</b>	
12:15-1:15 pm	<p><b>Interactive Discussion – Targeted Therapies: Pre-Clinical and Pharmacologic Considerations</b></p> <ul style="list-style-type: none"> <li>Describe the methodology and model systems utilized to assess efficacy, tolerability, and dosing schedules for targeted therapeutics</li> <li>Recognize gaps in our knowledge regarding optimal dose and schedule for targeted therapeutics in veterinary cancer patients</li> <li>Understand limitations of extrapolating preclinical safety and tolerability data of targeted therapies to veterinary patients with cancer</li> <li>Understand the difference between FDA-approved and 503A and 503B compounded products</li> <li>Incorporate information discussed in this session into your clinical practice and client discussions</li> </ul>	<p><i>Dr. Luke Wittenberg, Dr. Heather Gardner, Dr. Lauren Forsythe</i></p> <p><i>Moderator: Dr. Sue Lana</i></p>
1:15-1:30 pm	<b>Break</b>	

**Novel Oncology Therapeutics: Targeting Hope**  
**Live Virtual Course**  
**August 25, 2023**

*Premier Sponsor*



DAY 1 (continued) Friday, August 25, 2023		
Time (Mountain Time)	Topic	Presenter(s)
1:30-2:00 pm	<p><b>Lunch &amp; Learn – Presented by Merck</b> <b>Immune Checkpoint Inhibitors: Oh, the Places (We Hope!) You’ll Go</b></p> <ul style="list-style-type: none"> <li>Understand the pros and cons of several potential biomarkers for successful use of immune checkpoint inhibition therapy and review what we currently know about these biomarkers in veterinary medicine.</li> <li>Gain familiarity with the indications, administration, and safety profile of gilvetmab.</li> </ul>	<i>Dr. Laura Greene</i>
2:00-3:30 pm	<p><b>Lecture Series – Targeted Therapies: Clinical Applications, Combinations and Clinicians’ Experiences</b></p> <ul style="list-style-type: none"> <li>Become familiar with newer targeted therapies available in veterinary oncology</li> <li>Recognize gaps in our knowledge regarding optimal clinical application of targeted therapies in canine and feline cancers</li> <li>Describe the dosing strategies and potential toxicity profiles for protocols combining targeted therapies</li> <li>Incorporate information discussed in this session into your clinical practice and client discussions</li> </ul>	<i>Dr. Bridget Urie, Dr. Marilia Takada, Dr. Joelle Fenger, Dr. Mark Byrum</i>
3:30-3:45 pm	<b>Break</b>	
3:45-4:45 pm	<p><b>Interactive Discussion – Targeted Therapies: Clinical Applications, Combinations and Clinicians’ Experiences</b></p> <ul style="list-style-type: none"> <li>Become familiar with newer targeted therapies available in veterinary oncology</li> <li>Recognize gaps in our knowledge regarding optimal clinical application of targeted therapies in canine and feline cancers</li> <li>Describe the dosing strategies and potential toxicity profiles for protocols combining targeted therapies</li> <li>Incorporate information discussed in this session into your clinical practice and client discussions</li> </ul>	<i>Dr. Bridget Urie, Dr. Marilia Takada, Dr. Joelle Fenger, Dr. Mark Byrum</i>  <i>Moderator: Dr. Jenna Burton</i>
4:45 PM	<b>Closing Remarks</b>	<i>Dr. Jenna Burton, Dr. Joelle Fenger</i>